Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1,887 | 2 | 44.2% |
| Food and Beverage | $1,647 | 19 | 38.6% |
| Honoraria | $700.00 | 2 | 16.4% |
| Travel and Lodging | $30.96 | 2 | 0.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| La Jolla Pharmaceutical Company | $3,065 | 11 | $0 (2024) |
| Gilead Sciences, Inc. | $608.34 | 7 | $0 (2023) |
| ViiV Healthcare Company | $355.18 | 4 | $0 (2022) |
| PFIZER INC. | $124.74 | 1 | $0 (2018) |
| Novo Nordisk Inc | $65.09 | 1 | $0 (2017) |
| Melinta Therapeutics, LLC | $46.18 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $919.45 | 7 | La Jolla Pharmaceutical Company ($873.27) |
| 2023 | $2,359 | 8 | La Jolla Pharmaceutical Company ($2,069) |
| 2022 | $569.99 | 6 | ViiV Healthcare Company ($355.18) |
| 2021 | $122.39 | 1 | La Jolla Pharmaceutical Company ($122.39) |
| 2018 | $228.46 | 2 | PFIZER INC. ($124.74) |
| 2017 | $65.09 | 1 | Novo Nordisk Inc ($65.09) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/01/2024 | La Jolla Pharmaceutical Company | — | Food and Beverage | In-kind items and services | $71.49 | General |
| 11/01/2024 | La Jolla Pharmaceutical Company | — | Food and Beverage | In-kind items and services | $70.82 | General |
| 10/17/2024 | La Jolla Pharmaceutical Company | — | Honoraria | Cash or cash equivalent | $350.00 | General |
| 10/17/2024 | La Jolla Pharmaceutical Company | — | Travel and Lodging | In-kind items and services | $15.48 | General |
| 10/14/2024 | Melinta Therapeutics, LLC | — | Food and Beverage | In-kind items and services | $46.18 | General |
| 10/10/2024 | La Jolla Pharmaceutical Company | — | Honoraria | Cash or cash equivalent | $350.00 | General |
| 10/10/2024 | La Jolla Pharmaceutical Company | — | Travel and Lodging | In-kind items and services | $15.48 | General |
| 10/26/2023 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $25.66 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 10/11/2023 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Consulting Fee | Cash or cash equivalent | $1,685.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/11/2023 | La Jolla Pharmaceutical Company | XACDURO (Drug) | Consulting Fee | In-kind items and services | $201.51 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 10/11/2023 | La Jolla Pharmaceutical Company | XERAVA (Drug), XACDURO | Food and Beverage | In-kind items and services | $157.22 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 08/02/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $121.86 | General |
| 06/15/2023 | Gilead Sciences, Inc. | Descovy (Drug) | Food and Beverage | In-kind items and services | $121.86 | General |
| Category: HIV | ||||||
| 03/30/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.83 | General |
| 03/01/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.26 | General |
| 10/13/2022 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $104.00 | General |
| Category: HIV | ||||||
| 09/01/2022 | ViiV Healthcare Company | APRETUDE (Biological) | Food and Beverage | In-kind items and services | $115.21 | General |
| Category: HIV | ||||||
| 08/31/2022 | Gilead Sciences, Inc. | Biktarvy (Drug) | Food and Beverage | In-kind items and services | $92.94 | General |
| Category: HIV | ||||||
| 08/04/2022 | Gilead Sciences, Inc. | Descovy (Drug) | Food and Beverage | In-kind items and services | $121.87 | General |
| Category: HIV | ||||||
| 06/29/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $23.73 | General |
| Category: HIV | ||||||
| 05/19/2022 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $112.24 | General |
| Category: HIV | ||||||
| 11/17/2021 | La Jolla Pharmaceutical Company | XERAVA (Drug) | Food and Beverage | In-kind items and services | $122.39 | General |
| Category: TETRACYCLINE CLASS ANTIBACTERIAL | ||||||
| 09/18/2018 | PFIZER INC. | ELIQUIS (Drug) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 05/10/2018 | Gilead Sciences, Inc. | Epclusa (Drug) | Food and Beverage | In-kind items and services | $103.72 | General |
| Category: HCV | ||||||
| 07/13/2017 | Novo Nordisk Inc | Tresiba (Drug) | Food and Beverage | In-kind items and services | $65.09 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 80 | 161 | $38,456 | $11,949 |
| 2022 | 4 | 78 | 161 | $37,369 | $11,687 |
All Medicare Procedures & Services
8 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 32 | 88 | $16,896 | $5,493 | 32.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 15 | 31 | $9,030 | $2,911 | 32.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 16 | 25 | $6,750 | $1,803 | 26.7% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 17 | 17 | $5,780 | $1,742 | 30.1% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 18 | 55 | $14,025 | $4,451 | 31.7% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 29 | 68 | $12,104 | $3,826 | 31.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 17 | 24 | $6,480 | $1,920 | 29.6% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 14 | 14 | $4,760 | $1,490 | 31.3% |
About Dr. Joseph Hornak, MD
Dr. Joseph Hornak, MD is a Infectious Disease healthcare provider based in Galveston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/01/2017. The National Provider Identifier (NPI) number assigned to this provider is 1396273454.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Hornak, MD has received a total of $4,265 in payments from pharmaceutical and medical device companies, with $919.45 received in 2024. These payments were reported across 25 transactions from 6 companies. The most common payment nature is "Consulting Fee" ($1,887).
As a Medicare-enrolled provider, Hornak has provided services to 158 Medicare beneficiaries, totaling 322 services with total Medicare billing of $23,636. Data is available for 2 years (2022–2023), covering 8 distinct procedure/service records.
Practice Information
- Specialty Infectious Disease
- Location Galveston, TX
- Active Since 06/01/2017
- Last Updated 07/14/2022
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1396273454
Products in Payments
- XACDURO (Drug) $1,887
- XERAVA (Drug) $305.27
- Descovy (Drug) $243.73
- APRETUDE (Biological) $219.21
- CABENUVA (Biological) $135.97
- ELIQUIS (Drug) $124.74
- Epclusa (Drug) $103.72
- Biktarvy (Drug) $92.94
- Tresiba (Drug) $65.09
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Infectious Disease Doctors in Galveston
Dr. David Reynoso, M.d., Ph.d, M.D., PH.D
Infectious Disease — Payments: $6,901
Dennis Walling, Md, MD
Infectious Disease — Payments: $1,766
Daniel Stanton, Md, MD
Infectious Disease — Payments: $384.37
Juan Sarria, Md, MD
Infectious Disease — Payments: $363.02
April Mcdougal, D.o, D.O
Infectious Disease — Payments: $143.51
Lucas Blanton, Md, MD
Infectious Disease — Payments: $71.75